IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026)
IGC Pharma's (IGC) quarterly Total Non-Current Liabilities came in at $191000.0 in Q1 2026, up 19.38% year-over-year from $160000.0 in Q1 2025, and up 43.61% quarter-over-quarter from $133000.0 in Q4 2025.
Powered by 
Analysis
IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Total Non-Current Liabilities for 16 consecutive years, with $191000.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 19.38% year-over-year to $191000.0 in Q1 2026; TTM through Mar 2026 was $191000.0, a 19.38% increase from a year earlier, with the FY2026 full-year figure at $191000.0, up 19.38% from the prior year.
- Total Non-Current Liabilities was $191000.0 for Q1 2026 at IGC Pharma, up from $133000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $501000.0 in Q1 2022 and troughed at $133000.0 in Q4 2025.
- A 5-year average of $273941.2 and a median of $241000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 40.0% in 2024 and increased 19.38% in 2026, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $397000.0 in 2022, then slumped by 31.99% to $270000.0 in 2023, then sank by 40.0% to $162000.0 in 2024, then dropped by 17.9% to $133000.0 in 2025, then jumped by 43.61% to $191000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $191000.0 (Q1 2026), $133000.0 (Q4 2025), and $137000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | IGC Pharma | 27.77 Mn | 27.51 Mn | - | 191,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 191,000.00 |
| Dec 31, 2025 | 133,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 340,000.00 |
| Mar 31, 2023 | 369,000.00 |
| Dec 31, 2022 | 397,000.00 |
| Sep 30, 2022 | 432,000.00 |
| Jun 30, 2022 | 467,000.00 |
| Mar 31, 2022 | 501,000.00 |
| Dec 31, 2021 | 534,000.00 |
| Sep 30, 2021 | 565,000.00 |
| Jun 30, 2021 | 595,000.00 |